Sai Life Sciences share price
NSE: SAILIFEBSE: 544306Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 23 Oct 2026. Previous close ₹1,395.90.
- Next results date: the board meets on 5 Nov 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹29,639 Cr329th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 6 Aug 2026
- 81.9
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 14 May 2026
- 11.9
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 6 Aug 2026
- 15.7%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 6 Aug 2026
- 18.7%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 14 May 2026
- 0.04
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 6,69,41147.5% delivered
Results
Consolidated; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 6 Aug
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹554 Crdown 7.95%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹73 Crdown 29.69%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 13.2%
Revenue by year
Net profit by year, a loss in red
| ₹ crore | Dec 2024Filed 7 Feb | Mar 2025Filed 12 Jun | Jun 2025Filed 7 Aug | Sep 2025Filed 6 Nov | Dec 2025Filed 5 Feb | Mar 2026Filed 14 May | Jun 2026Filed 6 Aug |
|---|---|---|---|---|---|---|---|
| Revenue | 440 | 580 | 496 | 537 | 556 | 602 | 554 |
| Net profit | 54 | 88 | 60 | 84 | 100 | 104 | 73 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 12.2% | 15.2% | 12.2% | 15.6% | 18.0% | 17.3% | 13.2% |
Business segments
In the year to Mar 2026 the company reports one business segment, Contract Research, Development and Manufacturing (CRDMO), which carries all its revenue.
Valuation
Today, against the company's own history. Dividend yield is not shown: no dividend in the years on record.PE ratio and valuation history
At or below today's level on 79% of 238 trading days since Nov 2025.
At or below today's level on 80% of 247 trading days over the last year.
At or below today's level on 79% of 238 trading days since Nov 2025.
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +27.8% | +101.8% | −36.7% | 0.0% |
Mutual funds holding it
175 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 64 of the 93 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future. 1 more fund filed its first portfolio on record, holding it.Mutual fund holdings
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 7
- AddedAdded. Funds that held more shares than at the end of the month before.
- 34
- CutCut. Funds that held fewer shares than at the end of the month before.
- 59
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 74
| Fund | |||
|---|---|---|---|
 Nippon India Small Cap FundNippon India Mutual Fund | 65,63,832 | 1.24% | ₹1,000.7 Cr |
 Invesco India Small Cap FundInvesco Mutual Fund | 54,40,617 | 5.14% | ₹829.4 Cr |
| Invesco India Large & Mid Cap FundInvesco Mutual Fund | 42,83,799 | 5.36% | ₹653.1 Cr |
| Nippon India Multi Cap FundNippon India Mutual Fund | 39,68,891 | 1.13% | ₹605.1 Cr |
 Axis Small Cap FundAxis Mutual Fund | 37,02,004 | 1.84% | ₹564.4 Cr |
| Invesco India Mid Cap FundInvesco Mutual Fund | 34,16,927 | 3.31% | ₹520.9 Cr |
 HSBC Small Cap FundHSBC Mutual Fund | 26,79,487 | 2.21% | ₹408.5 Cr |
| Nippon India Pharma FundNippon India Mutual Fund | 23,55,745 | 3.92% | ₹359.1 Cr |
 DSP Healthcare FundDSP Mutual Fund | 16,02,712 | 6.52% | ₹244.3 Cr |
 Aditya Birla Sun Life Small Cap FundAditya Birla Sun Life Mutual Fund | 12,63,192 | 3.15% | ₹192.6 Cr |
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Sai Life Sciences in market cap.
Where the company sits among the companies nearest its size
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Gland PharmaGLAND | 46,645 | 41.3 | 4.5 | 24.9 | +17.6% | +46.5% | 11.6% | 12.4% | 0.71% |
 Ajanta PharmaAJANTPHARM | 41,035 | 36.2 | 9.1 | 28.0 | +20.2% | +22.0% | 27.3% | 27.2% | 1.83% |
 GlaxoSmithKline PharmaceuticalsGLAXO | 40,737 | 38.1 | 18.0 | 29.1 | +5.8% | +12.4% | 50.6% | 56.3% | 2.37% |
 Emcure PharmaceuticalsEMCURE | 33,586 | 33.2 | 6.8 | 17.5 | +18.4% | +35.9% | 21.5% | 25.2% | 0.20% |
 WockhardtWOCKPHARMA | 29,276 | 71.6 | 5.9 | 40.4 | +18.4% | – | 8.8% | 7.4% | 0.00% |
 Acutaas ChemicalsACUTAAS | 25,689 | 66.5 | 15.5 | 47.0 | +40.9% | +104.3% | 26.1% | 29.1% | 0.08% |
 Piramal PharmaPPLPHARMA | 25,438 | – | 3.1 | 29.4 | +0.8% | −419.8% | −3.9% | 1.1% | 0.00% |
 Neuland LaboratoriesNEULANDLAB | 24,204 | 48.6 | 12.9 | 31.5 | +78.3% | +182.6% | 29.3% | 32.1% | 0.18% |
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
19 Oct · Analysts
12 Oct · Disclosure
Sep 2026
Sai Life Sciences share price by year
Each calendar year to 2025.Sai Life Sciences share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 908.40 | +20.9% | 925.90 | 640.25 |
| 2024 | 751.20 | – | 764.65 | 703.65 |
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 23 Oct 2026 | 1,391.90 | 1,429.00 | 1,382.90 | 1,395.30 | 1,402.51 | 6,69,411 | 47.5% |
| 22 Oct 2026 | 1,390.00 | 1,407.80 | 1,371.00 | 1,395.90 | 1,393.29 | 1,76,826 | 46.0% |
| 21 Oct 2026 | 1,395.00 | 1,399.10 | 1,360.60 | 1,393.60 | 1,380.63 | 4,27,119 | 49.7% |
| 19 Oct 2026 | 1,381.00 | 1,412.60 | 1,370.40 | 1,395.90 | 1,393.76 | 2,90,389 | 52.2% |
| 16 Oct 2026 | 1,400.00 | 1,403.30 | 1,371.40 | 1,389.40 | 1,389.08 | 6,39,029 | 57.5% |
| 15 Oct 2026 | 1,432.00 | 1,444.70 | 1,390.00 | 1,394.70 | 1,407.88 | 6,31,706 | 65.2% |
| 14 Oct 2026 | 1,456.50 | 1,456.60 | 1,421.30 | 1,432.10 | 1,434.67 | 4,06,225 | 61.2% |
| 13 Oct 2026 | 1,472.00 | 1,479.80 | 1,426.70 | 1,462.30 | 1,444.93 | 7,24,740 | 55.5% |
| 12 Oct 2026 | 1,489.00 | 1,505.20 | 1,464.00 | 1,471.30 | 1,481.32 | 3,80,927 | 56.5% |
| 9 Oct 2026 | 1,509.80 | 1,518.90 | 1,470.60 | 1,487.90 | 1,489.39 | 4,29,336 | 59.6% |
About Sai Life Sciences
Sai Life Sciences is a contract research, development and manufacturing organisation (CRDMO) headquartered in Hyderabad, India. It works for biotech and pharmaceutical companies, taking molecules from discovery through development to commercial manufacturing. Its work centres on small molecule new chemical entities, with growing capabilities in peptides, antibody-drug conjugates and oligonucleotides. It partners with more than 300 global pharmaceutical and biotechnology companies, and its large pharma clients include 19 of the top 25 global pharmaceutical companies.
The business operates in two segments. The CRO segment covers discovery services: medicinal chemistry, integrated biology and pharmacology research, DMPK and toxicology studies, and preclinical research. The CDMO segment covers process development, analytical development and validation, clinical trial supplies, API manufacturing and commercial supply. Customers work with it through a full-time equivalent model, with dedicated scientific teams, or a fee-for-service model, with defined project deliverables. Its commercial portfolio stands at 34 molecules.
The company has an integrated research campus in Genome Valley, Hyderabad, and a cGMP manufacturing site at Bidar, India, with 700 KL of capacity serving markets including the USA, UK, EU and Japan. Closer to customers, it runs a process R&D laboratory at Alderley Park in Manchester, UK, and an exploratory biology laboratory in Greater Boston, USA.
It was incorporated in 1999 in Hyderabad and began operations at Unit I there, providing medicinal chemistry services to US biotech companies. It later acquired manufacturing capacity at Bidar. Over the years it has taken investment from Sequoia Capital, MPM Capital, TATA Capital, HBM Healthcare Investments and TPG Capital.
- Legal name
- Sai Life Sciences Limited
- NSE symbol
- SAILIFE
- BSE code
- 544306
- ISIN
- INE570L01029
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Dec 2024
- Face value
- ₹1
- CIN
- L24110TG1999PLC030970
- Corporate identity number, the registrar of companies' code for it